Cáncer de páncreas: segunda línea, ¿tenemos ahora una opción real de secuenciación?

21 / 24

Potential treatment sequencing
approach for MPC in 2018?
FOLNOX
Nab-paclitaxel +
gemcitabine
(if no neuropathy)
Gemcitabine
FOLFIRINOX
Nab-paclitaxel +
gemcitabine
MM-398 +
5-FU/LV
OFF
Capecitabine or
5-FU
MM-398 + 5-FU/LV
(depending on
prior exposure)
1st line 2nd line 3rd line
NOTE: Nab-paclitaxel is licensed for use in combination
with gemcitabine as 1st-line therapy for patients with MPC
Nab-paclitaxel?
(depending on
prior exposure)
mFOLFOX6 or
CAPOX
Platinum-based tx
(depending on
prior exposure)
Supported by RCT data
Supported by retrospective data or
small, single arm trials